Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620603 · ClinicalTrials.gov registry record · Phase 1
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
A Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis, sponsored by Case Comprehensive Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04620603: Active Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis, sponsored by Case Comprehensive Cancer Center.
NCT04620603 is a Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis that is active but no longer recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 5 participants, below the 126-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04620603, a Phase 1 study of Renal Cell Cancer and Urothelial Cancer of Renal Pelvis, is active but no longer recruiting, sponsored by Case Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.
Primary Outcome
iRECIST was developed by the RECIST working group for the use of RECIST version 1.1 in cancer immunotherapy trials, to ensure consistent design and data collection. ORR is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on iRECIST or RECIST v1.1 at any time during the study. CR = disappearance of all target lesions, PR is =\>30% decrease in sum of diameters of target lesions, progressive disease (PD) is \>20% increase in sum of diameters of ta
Conditions Studied
Interventions
- RADIATION Low Dose Rate Brachytherapy (LDR)
- DRUG Standard-of-Care Immunotherapy
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 1 |
What the registry record for NCT04620603 still lists
NCT04620603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 126-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Renal Cell Cancer appearing as the primary indexed condition, and to 2 interventions - of which Low Dose Rate Brachytherapy (LDR) is the first listed.
NCT04620603 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04620603 about?
NCT04620603 is a clinical study titled "Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer". This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.
What is the current status of trial NCT04620603?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-05-27. Estimated completion is 2026-02-01.
What conditions does trial NCT04620603 study?
This clinical trial studies the following conditions: Renal Cell Cancer, Urothelial Cancer of Renal Pelvis, Cutaneous Malignant Melanoma.
What interventions are being tested in trial NCT04620603?
The interventions under investigation include: Low Dose Rate Brachytherapy (LDR) (RADIATION), Standard-of-Care Immunotherapy (DRUG).
Who is sponsoring clinical trial NCT04620603?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04620603 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04620603's enrollment target sits among peer trials
5 10th of 10 the lowest of 10 other Renal Cell Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
RECRUITING · Phase 1
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
COMPLETED
-
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI